Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;29(3):115-119.
doi: 10.1038/ijir.2017.5. Epub 2017 Mar 16.

Time-course changes of nLDL-induced erectile dysfunction

Affiliations

Time-course changes of nLDL-induced erectile dysfunction

N Durmus et al. Int J Impot Res. 2017 May.

Abstract

Hyperlipidemia is an important risk factor for atherosclerosis and is frequently seen in patients with erectile dysfunction (ED). This study was designed to evaluate whether the acute effect of native low-density lipoprotein (nLDL) on intracavernosal pressure (ICP) is reversible and related to plasma asymmetrical dimethylarginine (ADMA), endogenous inhibition of endothelial nitric oxide synthase (eNOS) levels and eNOS expression in cavernous tissues. Hyperlipidemia was induced by a single dose of intravenous 4 mg kg-1 nLDL. Experiments were performed 72 h (72H), 2 weeks (2W) and 8 weeks (8W) after nLDL injection. Endothelium-dependent relaxations, the ratio of ICP to mean arterial pressure (MAP; ICP/MAP), plasma ADMA levels and eNOS mRNA and protein levels were evaluated. The ICP/MAP ratio decreased in both the 2W and 8W groups. Endothelium-dependent relaxation responses to acetylcholine in the rat thoracic aorta were damaged in the 8W group. Plasma ADMA levels increased in the 8W group. mRNA expression of eNOS decreased in a time-dependent manner, whereas the protein expression increased. These results suggest that acute nLDL injection-induced impairments in erectile functions during an 8-week period are irreversible and might be related to an increase in ADMA levels and changes in the regulation of the eNOS/NO pathway.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mayo Clin Proc. 2009 Feb;84(2):139-48 - PubMed
    1. J Urol. 1994 Jan;151(1):198-205 - PubMed
    1. Urol Int. 2010;85(1):112-7 - PubMed
    1. Int J Hypertens. 2012;2012:627278 - PubMed
    1. Int J Impot Res. 2005 Nov-Dec;17(6):523-6 - PubMed

LinkOut - more resources